Cargando…

Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813471/
http://dx.doi.org/10.1007/s40278-022-09642-0
_version_ 1784644864593362944
collection PubMed
description
format Online
Article
Text
id pubmed-8813471
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88134712022-02-04 Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report Reactions Weekly Case Report Springer International Publishing 2022-02-05 2022 /pmc/articles/PMC8813471/ http://dx.doi.org/10.1007/s40278-022-09642-0 Text en © Springer International Publishing AG 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title_full Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title_fullStr Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title_full_unstemmed Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title_short Dexamethasone/tocilizumab: Lack of efficacy during off label use: case report
title_sort dexamethasone/tocilizumab: lack of efficacy during off label use: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813471/
http://dx.doi.org/10.1007/s40278-022-09642-0